Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
Investing.com -- Ernexa Therapeutics Inc (NASDAQ:ERNA) stock surged 65.8% after announcing a manufacturing collaboration with Cellipont Bioservices to advance its lead cancer cell therapy toward clinical trials.
The partnership will focus on Engineering, Differentiation, and Production activities for ERNA-101, Ernexa’s cell therapy being developed for ovarian cancer treatment. Cellipont will support the current Good Manufacturing Practice development and scale-up of the manufacturing process as the therapy heads toward clinical trials.
ERNA-101 is based on Ernexa’s technology that engineers induced pluripotent stem cells into induced mesenchymal stem cells (iMSCs), which have a unique ability to migrate toward tumors. The therapy is designed as an allogeneic, off-the-shelf treatment that doesn’t require patient-specific cell harvesting.
"This collaboration marks an important milestone in advancing our iMSC platform, which we believe has the potential to reshape the treatment landscape for patients with advanced solid tumors," said Sanjeev Luther, President and CEO of Ernexa Therapeutics.
In preclinical studies presented at this year’s AACR and ASCO annual meetings, ERNA-101 demonstrated potential to reprogram immunologically "cold" tumors into "hot" ones, increasing immune cell infiltration and suppressing tumor growth.
Darren Head, CEO of Cellipont Bioservices, noted that supporting the development of synthetic, allogeneic iMSC therapies like ERNA-101 aligns with the company’s commitment to enabling scientific innovation through collaborative cell therapy manufacturing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.